東華大學圖書館 |

語系: 繁體中文

說明(常見問題)

回圖書館首頁

手機版館藏查詢

登入

回首頁

切換: 標籤 | MARC模式 | ISBD

A vaccinia recombinant virus: Compar...

Hanlon, Cathleen Alma.

FindBook

Google Book

Amazon

博客來

A vaccinia recombinant virus: Comparative evaluations among free-ranging, immunocompetent, and immunodeficient hosts.

紀錄類型:	書目-電子資源 : Monograph/item
正題名/作者:	A vaccinia recombinant virus: Comparative evaluations among free-ranging, immunocompetent, and immunodeficient hosts./
作者:	Hanlon, Cathleen Alma.
出版者:	Ann Arbor : ProQuest Dissertations & Theses, : 1994,
面頁冊數:	205 p.
附註:	Source: Dissertation Abstracts International, Volume: 55-05, Section: B, page: 1767.
Contained By:	Dissertation Abstracts International55-05B.
標題:	Veterinary science. -
電子資源:	http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=9427544

A vaccinia recombinant virus: Comparative evaluations among free-ranging, immunocompetent, and immunodeficient hosts.
Hanlon, Cathleen Alma.

A vaccinia recombinant virus: Comparative evaluations among free-ranging, immunocompetent, and immunodeficient hosts. - Ann Arbor : ProQuest Dissertations & Theses, 1994 - 205 p.

Source: Dissertation Abstracts International, Volume: 55-05, Section: B, page: 1767.

Thesis (Ph.D.)--University of Pennsylvania, 1994.

An orally efficacious vaccinia-rabies glycoprotein (V-RG) recombinant virus holds promise for wildlife rabies control. Due to thymidine kinase gene inactivation, the V-RG virus is attenuated. However, it may retain parental vaccinia characteristics for accidental mucous membrane infection and other complications in immunocompromised hosts. In these studies, neonatal, prednisolone-treated, and CDV$\sp1$-infected raccoons, FIV+, FeLV+, and dually-infected FeLV+, FIP+ cats, and athymic nude and SCID mice were utilized to evaluate V-RG in host models for specific vaccinia contraindications. Additionally, during the first North American V-RG field release on Parramore Island, VA, 887 free-ranging raccoons were live-trapped and examined for vaccinia-like lesions. No lesions suggestive of V-RG virus were demonstrated. The V-RG virus was recovered from tonsils of two, biomarker-positive vaccination area raccoons on days two and four following bait distribution. Survivorship was not different between baited and non-baited areas. In laboratory studies among 52 raccoons, two received 20 times the field dose per os, one dam nursing four 17 day-old kits received 10 times the field dose, eight raccoons received one vaccine-laden bait each, six were inoculated with one field dose at seven conjunctival and oral mucosal sites, 14 were less than 25 days-old upon oral, intradermal, ocular, or intranasal exposure, 21 received V-RG intradermally of which four were pretreated with prednisolone, and two had canine distemper. Notable findings in raccoons were limited to focal microscopic ulcerations at scarification sites. In 24 experimentally-infected FIV+, FeLV+, FeLV+ and FIP+, and uninfected cats, oral and intradermal inoculation of V-RG vaccine produced no clinically detectable adverse effects. In athymic nude mice, multi-systemic infection followed severe intradermal V-RG inoculation, but with a decrease in positive tissues and viral titers over time. In SCID mice, V-RG was innocuous by the oral route. Parenteral V-RG inoculation produced progressive lesions but at a significantly slower rate than with vaccinia. Administration of vaccinia immune globulin and hydroxyphosphonylmethoxypropylcytosine (HPMPC) resulted in regression of V-RG infection in SCID mice. ftn$\sp1$CDV-Canine distemper virus. FIV-Feline immunodeficiency virus. FeLV-Feline leukemia virus. FIP-Feline infectious peritonitis. SCID-Severe combined immunodeficiency.Subjects--Topical Terms:

3172798
Veterinary science.

A vaccinia recombinant virus: Comparative evaluations among free-ranging, immunocompetent, and immunodeficient hosts.
LDR:03411nmm a2200289 4500 001 2116958
005 20170508094400.5
008 180830s1994 ||||||||||||||||| ||eng d
035 $a (MiAaPQ)AAI9427544
035 $a AAI9427544
040 $a MiAaPQ $c MiAaPQ
100 1 $a Hanlon, Cathleen Alma. $3 3278708
245 1 2 $a A vaccinia recombinant virus: Comparative evaluations among free-ranging, immunocompetent, and immunodeficient hosts.
260 1 $a Ann Arbor : $b ProQuest Dissertations & Theses, $c 1994
300 $a 205 p.
500 $a Source: Dissertation Abstracts International, Volume: 55-05, Section: B, page: 1767.
500 $a Supervisor: Charles E. Rupprecht.
502 $a Thesis (Ph.D.)--University of Pennsylvania, 1994.
520 $a An orally efficacious vaccinia-rabies glycoprotein (V-RG) recombinant virus holds promise for wildlife rabies control. Due to thymidine kinase gene inactivation, the V-RG virus is attenuated. However, it may retain parental vaccinia characteristics for accidental mucous membrane infection and other complications in immunocompromised hosts. In these studies, neonatal, prednisolone-treated, and CDV$\sp1$-infected raccoons, FIV+, FeLV+, and dually-infected FeLV+, FIP+ cats, and athymic nude and SCID mice were utilized to evaluate V-RG in host models for specific vaccinia contraindications. Additionally, during the first North American V-RG field release on Parramore Island, VA, 887 free-ranging raccoons were live-trapped and examined for vaccinia-like lesions. No lesions suggestive of V-RG virus were demonstrated. The V-RG virus was recovered from tonsils of two, biomarker-positive vaccination area raccoons on days two and four following bait distribution. Survivorship was not different between baited and non-baited areas. In laboratory studies among 52 raccoons, two received 20 times the field dose per os, one dam nursing four 17 day-old kits received 10 times the field dose, eight raccoons received one vaccine-laden bait each, six were inoculated with one field dose at seven conjunctival and oral mucosal sites, 14 were less than 25 days-old upon oral, intradermal, ocular, or intranasal exposure, 21 received V-RG intradermally of which four were pretreated with prednisolone, and two had canine distemper. Notable findings in raccoons were limited to focal microscopic ulcerations at scarification sites. In 24 experimentally-infected FIV+, FeLV+, FeLV+ and FIP+, and uninfected cats, oral and intradermal inoculation of V-RG vaccine produced no clinically detectable adverse effects. In athymic nude mice, multi-systemic infection followed severe intradermal V-RG inoculation, but with a decrease in positive tissues and viral titers over time. In SCID mice, V-RG was innocuous by the oral route. Parenteral V-RG inoculation produced progressive lesions but at a significantly slower rate than with vaccinia. Administration of vaccinia immune globulin and hydroxyphosphonylmethoxypropylcytosine (HPMPC) resulted in regression of V-RG infection in SCID mice. ftn$\sp1$CDV-Canine distemper virus. FIV-Feline immunodeficiency virus. FeLV-Feline leukemia virus. FIP-Feline infectious peritonitis. SCID-Severe combined immunodeficiency.
590 $a School code: 0175.
650 4 $a Veterinary science. $3 3172798
650 4 $a Animal diseases. $3 3181862
650 4 $a Forestry. $3 895157
690 $a 0778
690 $a 0476
690 $a 0478
710 2 $a University of Pennsylvania. $3 1017401
773 0 $t Dissertation Abstracts International $g 55-05B.
790 $a 0175
791 $a Ph.D.
792 $a 1994
793 $a English
856 4 0 $u http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=9427544